Amyloid deposits and myocardial injury can cause elevation of cardiac biomarkers such as N-terminal pro-brain natriuretic peptide (NT-proBNP) or cardiac troponins.13–15 These biomarkers have accordingly been incorporated into different risk classification scores.16–19 While these staging systems are powerful prognostic tools for AL amyloidosis in general, the prediction of survival in patients with endomyocardial biopsy (EMB) proven cardiac involvement is not equally well investigated. Here, NPPB is linked to AL amyloidosis.